Search clinical trials for: Adrenergic Agonists

Total 16254 results

Henning Bundgaard

Completed

Beta 3 Agonist Treatment in Heart Failure (Beat-HF)

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Australia, Denmark
Aaron Cypess
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Obesity

United States
Yonsei University

Active, not recruiting

Effect of Mirabegron on Bladder Compliance

Patients With Low Bladder Compliance of 20ml/H2O or Less Despite Taking Anticholinergics

Korea, Republic of
General Hospital of Ningxia Medical University

Not yet recruiting

90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients

Adverse Effect
General Hospital of Ningxia Medical University

Not yet recruiting

90% Effective Dose of Norepinephrine Infusions Under Intensive and Standard Treatment

Adverse Effect
General Hospital of Ningxia Medical University

Not yet recruiting

90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment in Preeclamptic Patients

Adverse Effect
General Hospital of Ningxia Medical University

Recruiting

Intensive Versus Standard Treatment for Spinal Anesthesia-induced Hypotension

Outcome

China
GlaxoSmithKline

Completed

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

Overactive Bladder

United States
General Hospital of Ningxia Medical University

Not yet recruiting

90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment

Adverse Effect
GlaxoSmithKline

Completed

Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms

Overactive Bladder

Germany, Taiwan, Netherlands, Spain, Australia, Korea, Republic of, Latvia, Argentina, Slovenia, Finland, France, South Africa, Poland, New Zealand
General Hospital of Ningxia Medical University

Recruiting

Intensive Versus Standard Treatment for Spinal Anesthesia-induced Hypotension in Preeclamptic Patients

Adverse Effect

China
Technische Universität Dresden
Prof. Dr. Veit Roessner and PD Dr. Robert Waltereit jointly lead and conduct...

Unknown

Affective Dysregulation (AD) in Children With ADHD Treated by Guanfacin

Affective Dysregulation
GlaxoSmithKline

Completed

A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome (IBS)

Germany, Australia, France
George Papanicolaou Hospital

Unknown

Esmolol Versus Dexmedetomidine During Intracranial Procedures

Intracranial Aneurysm | Intracranial Neoplasms

Greece
General Hospital of Ningxia Medical University

Not yet recruiting

Intensive Versus Standard Treatment for Spinal Anesthesia-induced Hypotension on Maternal Hemodynamics

Outcome
Zhejiang Provincial People's Hospital

Recruiting

Effect of Mirabegron on Promoting Brown Adipose Tissue Activation

Tumour

China
General Hospital of Ningxia Medical University

Not yet recruiting

Intensive Versus Standard Treatment for Hypotension on Maternal Hemodynamics in Preeclamptic Patients

Adverse Effect
University of Alabama at Birmingham

Not yet recruiting

Efficacy of Topical Apraclonidine for the Treatment of Ocular Synkinesis

Synkinesis | Facial Nerve Palsy

United States
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Completed

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

Lower Urinary Tract Symptoms | Nocturia

United States
US Department of Veterans Affairs

Completed

Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder

United States
Aswan University Hospital

Completed

Intravenous Versus Peribulbar Dexmedetomidine for Strabismus Surgery in Adults

Squint

Egypt
Astellas Pharma Inc
Astellas Pharma Singapore Pte. Ltd.

Completed

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

Overactive Bladder

Japan, Korea, Republic of
Sarah Network of Rehabilitation Hospitals
University of Brasilia

Unknown

Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion (eMUNODEX)

Spondylolisthesis | Spondylolysis | Spine; Arthrosis | Spondylolysis, Multiple Sites in Spine

Brazil
Imperial College London

Recruiting

Noradrenergic Add-on Therapy With Guanfacine (NorAD)

Alzheimer Disease

United Kingdom
Vanderbilt University Medical Center
Massachusetts General Hospital; National Institute on Aging (NIA)

Active, not recruiting

Maximizing trEatment of Neurological Dysfunction Using INtravenous Guanfacine Study (MENDING)

Delirium | Critical Illness | Cognitive Impairment

United States
Johns Hopkins University
Astellas Pharma US, Inc.

Completed

Mirabegron For Erectile Dysfunction

Overactive Bladder | Urinary Incontinence | Erectile Dysfunction

United States
State University of New York at Buffalo
Astellas Pharma Inc

Withdrawn

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

Urinary Frequency/Urgency | Bladder Pain Syndrome | Bladder Irritable

United States
Mansoura University

Unknown

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Prostatic Neoplasms | Erectile Dysfunction | BPH | Prostate Hyperplasia | Erectile Abnormalities

Egypt
Vanderbilt University Medical Center

Completed

Guanfacine for PONV and Pain After Sinus Surgery

Pain, Postoperative | Postoperative Nausea and Vomiting

United States
Fundación Centro Nacional de Investigaciones Cardiovasculares...
Hospital Clinic of Barcelona; Fundació Institut de Recerca de l'Hospital de... and other collaborators

Unknown

Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE-HF)

Heart Failure | Pulmonary Hypertension | Mirabegron | Pulmonary Vascular Resistance Abnormality
Karolinska Institutet

Completed

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

Overactive Bladder

Sweden
Yale University
National Institute on Aging (NIA)

Completed

Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects

Cognitive Aging

United States
Astellas Pharma Inc

Completed

A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex

Healthy Volunteers | Pharmacokinetics of Mirabegron

France
Astellas Pharma China, Inc.

Completed

Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers

Healthy Chinese Volunteers

China
Peking Union Medical College Hospital

Not yet recruiting

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

Overactive Bladder
National Institute of Neurological Disorders and...

Terminated

Oral Guanabenz for Multiple Sclerosis

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States
CHU de Quebec-Universite Laval

Completed

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder (Add-on-Mira)

Overactive Bladder | Urinary Incontinence
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH)

Terminated

Pharmacology of Cognition in Schizotypal Personality Disorder

Personality Disorders | Schizotypal Personality Disorder

United States
National Center for Research Resources (NCRR)
Yale University

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

Tourette Syndrome
Taipei Veterans General Hospital, Taiwan

Recruiting

Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover Trial

Overactive Bladder Syndrome

Taiwan
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc.; Sisters of the Third Order of...

Terminated

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

Pain | Urinary Bladder, Overactive | Lower Urinary Tract Symptoms

United States
University of Florida
National Institute of General Medical Sciences (NIGMS)

Terminated

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

Pulmonary Hypertension | Heart Failure With Preserved Ejection Fraction | Diastolic Heart Failure

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Guanfacine Clinical Trial for Smoking Cessation

Smoking Cessation

United States
The University of Texas Health Science Center at...

Completed

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. Mirabegron (SCIMYR)

Cognitive Change | Spinal Cord Injuries | Neurogenic Bladder

United States
Loyola University
Astellas Pharma US, Inc.

Completed

Mirabegron and Urinary Urgency Incontinence

Overactive Bladder

United States
Yale University
National Institute on Drug Abuse (NIDA)

Completed

PK/PD Comparison of Guanfacine ER and IR

Smoking

United States
Heinrich-Heine University, Duesseldorf

Terminated

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients (BRIMOCAN)

Hand-foot Syndrome

Germany
Buddhist Tzu Chi General Hospital

Unknown

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

Urinary Bladder, Overactive

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Overactive Bladder | Cardiovascular Disease

Japan

Search clinical trials for: Adrenergic Agonists

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations